PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
16.52%
EBIT growth similar to TRVN's 17.11%. Walter Schloss might infer both firms share similar operational efficiencies.
16.52%
Operating income growth similar to TRVN's 17.11%. Walter Schloss would assume both share comparable operational structures.
16.61%
Net income growth comparable to TRVN's 17.09%. Walter Schloss might see both following similar market or cost trajectories.
17.14%
EPS growth similar to TRVN's 18.62%. Walter Schloss would assume both have parallel share structures and profit trends.
17.14%
Similar diluted EPS growth to TRVN's 18.62%. Walter Schloss might see standard sector or cyclical influences on both firms.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Dividend reduction while TRVN stands at 0.00%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
9.84%
Positive OCF growth while TRVN is negative. John Neff would see this as a clear operational advantage vs. the competitor.
13.18%
Positive FCF growth while TRVN is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2671.03%
Negative 10Y OCF/share CAGR while TRVN stands at 54.44%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
90.48%
5Y OCF/share CAGR 1.25-1.5x TRVN's 78.31%. Bruce Berkowitz would see if capital spending or working-capital efficiencies explain the difference.
83.42%
3Y OCF/share CAGR above 1.5x TRVN's 45.90%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
-2587.91%
Negative 10Y net income/share CAGR while TRVN is at 70.74%. Joel Greenblatt sees a major red flag in long-term profit erosion.
90.30%
5Y net income/share CAGR similar to TRVN's 82.29%. Walter Schloss might see both on parallel mid-term trajectories.
86.48%
3Y net income/share CAGR above 1.5x TRVN's 56.12%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
1551.35%
10Y equity/share CAGR above 1.5x TRVN's 520.73%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
-71.69%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-47.82%
Negative 3Y equity/share growth while TRVN is at 8.62%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
13.10%
Positive asset growth while TRVN is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
15.36%
Positive BV/share change while TRVN is negative. John Neff sees a clear edge over a competitor losing equity.
-14.09%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-7.82%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-4.34%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.